Sigyn Therapeutics (SIGY)
OTHER OTC:SIGY
Want to see SIGY full AI Analyst Report?
SIGY Stock Chart & Stats
$0.03
$0.00(0.00%)
At close: 4:00 PM EST
$0.03
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $5.00
Previous CloseN/A
Volume87.00
Average Volume (3M)1.22K
Market Cap
$62.61K
Enterprise Value$2.78M
Total Cash (Recent Filing)$85.57K
Total Debt (Recent Filing)$2.81M
Price to Earnings (P/E)―
Beta>-0.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding1,605,377
10 Day Avg. Volume2,995
30 Day Avg. Volume1,222
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market Cap44.48
Enterprise Value/Revenue482.29
Enterprise Value/Gross Profit964.59
Enterprise Value/Ebitda-1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Innovative TechnologyThe company's proprietary blood purification technology addresses critical medical needs, offering potential for strong market demand and strategic partnerships in healthcare.
Strategic PartnershipsEngaging in strategic partnerships can enhance technology distribution and application, driving long-term growth and market penetration in the healthcare sector.
Research Funding OpportunitiesAccess to research funding and government contracts can accelerate development and deployment of medical solutions, supporting innovation and financial sustainability.
Bears Say
Financial InstabilityPersistent financial difficulties indicate challenges in achieving profitability and sustainability, posing risks to long-term operational viability and investor confidence.
Negative Cash FlowNegative cash flow from operations suggests poor efficiency and high cash burn, necessitating reliance on external funding and impacting financial health.
Lack Of Revenue GrowthThe absence of revenue growth highlights challenges in market competitiveness and operational performance, limiting the company's ability to scale and generate profits.
Sigyn Therapeutics News
SIGY FAQ
What was Sigyn Therapeutics’s price range in the past 12 months?
Sigyn Therapeutics lowest stock price was $0.01 and its highest was $5.00 in the past 12 months.
What is Sigyn Therapeutics’s market cap?
Sigyn Therapeutics’s market cap is $62.61K.
When is Sigyn Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sigyn Therapeutics’s earnings last quarter?
Currently, no data Available
Is Sigyn Therapeutics overvalued?
According to Wall Street analysts Sigyn Therapeutics’s price is currently Overvalued.
Does Sigyn Therapeutics pay dividends?
Sigyn Therapeutics does not currently pay dividends.
What is Sigyn Therapeutics’s EPS estimate?
Sigyn Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sigyn Therapeutics have?
Sigyn Therapeutics has 1,605,377 shares outstanding.
What happened to Sigyn Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sigyn Therapeutics?
Currently, no hedge funds are holding shares in SIGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sigyn Therapeutics
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. The company is headquartered in San Diego, California.
Technical Analysis
Theriva Biologics
―
Indaptus Therapeutics
―
Revelation Biosciences
―
Dermata Therapeutics
―
Azitra Inc
―